Up 180% in a year, is it too late to buy Pro Medicus shares?

The question lingers.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro Medicus Ltd (ASX: PME) shares continue their meteoric rise, having recently nudged fresh new highs this week.

The healthcare stock is currently trading at $249.55 apiece, up an astonishing 180% over the past 12 months, having soared 32% this past month alone.

With such electrifying gains, the question we have now is twofold: Does this ASX healthcare darling still have room to run? Or has the ship already left for port? Let's see what the experts think.

Created with Highcharts 11.4.3Pro Medicus PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Why Pro Medicus shares are flying high

Pro Medicus is in the healthcare imaging technology business. So its profits aren't really that correlated to the broader business cycle. Would you skip an essential MRI in a recession? Exactly.

This year, Pro Medicus shares have been on a tear thanks to the tasty ingredient mix of record-breaking financial performance and massive contract wins.

Pro Medicus announced this week that it secured a ten-year, $330 million deal with US-based Trinity Health. This is the company's largest customer to date.

This follows a string of successes in the North American market, where its Visage 7 Enterprise Imaging Platform is becoming the go-to solution for radiologists.

The Trinity Health contract will see Pro Medicus' fully cloud-based system implemented across 93 hospitals, 107 continuing care locations, and 142 urgent care centres.

In total, this is 342 locations across each of these mediums.

Pro Medicus also reported a good set of FY24 results. Revenues were up 29% over the year, clipping to $161.5 million at the top line with 36% growth in net profit.

As such, every dollar of sales produced $1.24 in net profit, which is not a bad ratio to work with at all.

Is there still upside for Pro Medicus shares?

This is the big question for Pro Medicus shares. While the share price has skyrocketed, according to CommSec, the general consensus on the stock right now is a hold.

The rating is made up of three buys, four holds and one sell.

Goldman Sachs is one of those sitting around the fire in camp buy. The broker says the company's leadership in 'cloud-native imaging' and its growing pipeline of large contracts are bullish points.

In our view, PME is well positioned into FY25 given a full-year benefit of some large and high profile contracts, in addition to the accelerating frequency and size of new contract wins.

We see PME's software Visage 7 as an industry-leading solution with two distinct advantages relative to peers — speed and cloud capabilities — that have influenced the choice of PACS vendor. Given this, PME is benefiting from an industry network effect as more hospitals move to modern systems.

The broker also says moving into factors like artificial intelligence (AI) and cardiology could be the accelerant to Pro Medicus' growth fire.

Consensus projects earnings to expand by 25% per year out to FY26, which is a terrific business result.

Even still, the stock trades are more than 290x trailing earnings at the time of writing. In my view, this should be factored into the debate.

Foolish takeaway

Pro Medicus shares have delivered incredible returns this year. But the company's strong fundamentals and vast growth runway suggest there may still be upside for patient investors.

Even still, consensus rates it a hold.

As is always the case with managing investments, a long-term view is critical. Don't get caught up in the market's short-term machinations.

That way, you can participate in the good fortune of stocks like Pro Medicus, which has increased from $5 per share in 2017 to its current price, nearly 50x growth in value.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »